MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of
Oleclumab (MEDI9447) with or without Durvalumab in Combination with
Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.
* For Eligibility information, please click on the "Look up trial at NIH" link above *
Other eligibility criteria may apply.
Other exclusion criteria may apply.
Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Gastrointestinal Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.